How Yoshifumi lifted the paralysis of depression

To support persons with mental illness, Yoshifumi Kobayashi established a drug discovery venture business specializing in mental health. However, a few years later, he found that he suffered from depression without even realizing it himself. Hard days of battling against his mental illness had begun.

Read the story

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

Latest news

See all news

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

A better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person and community behind the disease. 

Our focus

Our sustainability strategy

Through our sustainability strategy, we mitigate business risks, reduce negative impacts, and address societal challenges where possible. We remain committed to UN Global Compact Principles, and contribute to seven of the 17 UN Sustainable Development Goals.

Read more

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

Read more
Mara Formentini on working at Lundbeck

Bringing your whole self to work and its rewards  

Read more
See all stories

Lundbeck at a glance